Process analysis of pluripotent stem cell differentiation to megakaryocytes to make platelets applying European GMP

• Published in: npj Regenerative medicine Vol. 6; no. 1; p. 27
• Main Authors: Lawrence, Moyra, Evans, Amanda, Moreau, Thomas, Bagnati, Marta, Smart, Matthew, Hassan, Enas, Hasan, Jahid, Pianella, Monica, Kerby, Julie, Ghevaert, Cedric
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.05.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/532/1360; 631/532/1542; 631/61/490; 692/700/565/2319; Biomaterials; Biomedical and Life Sciences; Biomedicine; Cell Biology; Good Manufacturing Practice; Immunology; Manufacturing; Perspective; Regenerative Medicine/Tissue Engineering; Stem Cells
• ISSN: 2057-3995; 2057-3995
• DOI: 10.1038/s41536-021-00138-y

Quality, traceability and reproducibility are crucial factors in the reliable manufacture of cellular therapeutics, as part of the overall framework of Good Manufacturing Practice (GMP). As more and more cellular therapeutics progress towards the clinic and research protocols are adapted to comply with GMP standards, guidelines for safe and efficient adaptation have become increasingly relevant. In this paper, we describe the process analysis of megakaryocyte manufacture from induced pluripotent stem cells with a view to manufacturing in vitro platelets to European GMP for transfusion. This process analysis has allowed us an overview of the entire manufacturing process, enabling us to pinpoint the cause and severity of critical risks. Risk mitigations were then proposed for each risk, designed to be GMP compliant. These mitigations will be key in advancing this iPS-derived therapy towards the clinic and have broad applicability to other iPS-derived cellular therapeutics, many of which are currently advancing towards GMP-compliance. Taking these factors into account during protocol design could potentially save time and money, expediting the advent of safe, novel therapeutics from stem cells.